KSE - Delayed Quote KRW

Shinpoong Pharmaceutical Co.,Ltd (019175.KS)

Compare
11,050.00
-150.00
(-1.34%)
At close: 3:30:30 PM GMT+9
Loading Chart for 019175.KS
  • Previous Close 11,200.00
  • Open 11,200.00
  • Bid 11,100.00 x --
  • Ask 11,190.00 x --
  • Day's Range 11,010.00 - 11,200.00
  • 52 Week Range 11,010.00 - 32,800.00
  • Volume 615
  • Avg. Volume 2,175
  • Market Cap (intraday) 354.862B
  • Beta (5Y Monthly) 2.11
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 14, 2025 - May 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 29, 2020
  • 1y Target Est --

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.

shinpoong.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 019175.KS

View More

Performance Overview: 019175.KS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

019175.KS
29.62%
KOSPI Composite Index (^KS11)
3.63%

1-Year Return

019175.KS
57.90%
KOSPI Composite Index (^KS11)
8.14%

3-Year Return

019175.KS
85.15%
KOSPI Composite Index (^KS11)
9.24%

5-Year Return

019175.KS
45.78%
KOSPI Composite Index (^KS11)
44.12%

Compare To: 019175.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 019175.KS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    574.14B

  • Enterprise Value

    573.37B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.59

  • Price/Book (mrq)

    2.25

  • Enterprise Value/Revenue

    2.59

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.96%

  • Return on Assets (ttm)

    -3.08%

  • Return on Equity (ttm)

    -5.81%

  • Revenue (ttm)

    221.09B

  • Net Income Avi to Common (ttm)

    -15.39B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    56.46B

  • Total Debt/Equity (mrq)

    21.15%

  • Levered Free Cash Flow (ttm)

    -5.18B

Research Analysis: 019175.KS

View More

Company Insights: 019175.KS

Research Reports: 019175.KS

View More

People Also Watch